Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
gptkb:prednisone
gptkb:dexamethasone gptkb:melphalan |
| gptkbp:approvalYear |
2003
|
| gptkbp:ATCCode |
L01XX32
|
| gptkbp:brand |
gptkb:Velcade
|
| gptkbp:CASNumber |
179324-69-7
|
| gptkbp:chemicalFormula |
C19H25BN4O4
|
| gptkbp:contraindication |
hypersensitivity to bortezomib
|
| gptkbp:developer |
gptkb:Takeda_Pharmaceutical_Company
gptkb:Millennium_Pharmaceuticals |
| gptkbp:eliminationHalfLife |
40 hours
|
| gptkbp:genericName |
gptkb:bortezomib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Velcade
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
protease inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:proteinBinding |
83%
|
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:sideEffect |
nausea
diarrhea fatigue peripheral neuropathy thrombocytopenia |
| gptkbp:usedFor |
gptkb:mantle_cell_lymphoma
multiple myeloma |
| gptkbp:bfsParent |
gptkb:Takeda
gptkb:Takeda_(Japan) |
| gptkbp:bfsLayer |
6
|